Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Summary

This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth

Timeline

Start

2007-04

Primary completion

—

Completion

2008-12

Outcome

Outcome not reported

Stopped (Enrollment): “Part B of the study was terminated early due to a lack of enrollment.”

Drugs

Indications